Global Ankylosing Spondylitis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In July 2023, Sandoz made a significant announcement regarding introducing Hyrimoz, a concentrated formulation, which signifies its entry into the field of immunology in the U.S. Hyrimoz HCF has received approval for the treatment of various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

• In January 2023, Amgen announced the availability of the first biosimilar to Humira, AMJEVITA, in the U.S. Biosimilars are extensively studied, FDA-approved treatments that potentially reduce cost. Amgen is uniquely qualified to do the same because of its track record in developing and producing biologics and decades of experience in inflammation.

The global ankylosing spondylitis market is witnessing significant growth due to increasing awareness, rising prevalence, and advancements in therapeutic options. Ankylosing spondylitis, a type of inflammatory arthritis affecting the spine and large joints, requires effective management strategies that have expanded market opportunities.

By drug, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) inhibitors, and other drug classes. NSAIDs remain the first-line treatment for reducing inflammation and pain. TNF inhibitors, including drugs such as Humira, Simponi, Remicade, Enbrel, Cimzia, and others, are gaining traction for their ability to slow disease progression and improve patient quality of life. Other drug classes, such as IL-17 inhibitors, are emerging as effective options for patients not responding to traditional therapies.

By route of administration, the market is divided into oral and parenteral options. Oral drugs are preferred for their ease of administration and patient convenience, while parenteral therapies, including injections and infusions, are often prescribed for severe cases requiring immediate and targeted effects. This differentiation allows for tailored treatment plans based on disease severity and patient needs.

The distribution channels for ankylosing spondylitis drugs include hospital pharmacies, retail pharmacies, and others. Hospital pharmacies dominate due to the availability of specialized treatments and access to advanced therapies under medical supervision. Retail pharmacies and online channels are also growing as they provide easy access to medications. Geographically, North America leads the market, driven by a well-established healthcare infrastructure and high awareness. Europe closely follows with a robust research landscape, while the Asia Pacific region shows potential growth due to increasing healthcare access and awareness. Markets in the Middle East, Africa, and Latin America are gradually evolving as healthcare infrastructure improves and awareness campaigns expand.

Global Ankylosing Spondylitis Segment Analysis

In this report, the Global Ankylosing Spondylitis Market has been segmented by Drug, Route of Administration, Distribution Channel, and Geography.

Global Ankylosing Spondylitis Market, Segmentation by Drug

The Global Ankylosing Spondylitis Market has been segmented by Drug into Non-Steroidal Anti Inflammatory Drug(NSAID), TNF Inhibitor- (Humira, Simponi, Remicade, Enbrel, Cimzia, Other TNF Inhibitors), Other Drug Classes.

NSAIDs are often the first line of treatment, offering symptomatic relief and improving mobility in patients.

The market for TNF inhibitors, including drugs such as Humira, Simponi, Remicade, Enbrel, Cimzia, and other similar biologics, is experiencing robust growth. These inhibitors have revolutionized the treatment landscape by not only managing symptoms but also slowing disease progression. TNF inhibitors are particularly beneficial for patients who do not respond adequately to NSAIDs, providing a targeted approach to reduce inflammation and prevent further joint damage.

Other drug classes, including IL-17 inhibitors and emerging biologics, are gaining attention for their potential to cater to patients who are unresponsive to conventional therapies. These drugs address the unmet medical needs in the market, offering alternative mechanisms of action to improve outcomes for patients with ankylosing spondylitis. The availability of diverse drug classes ensures a broader spectrum of treatment options, allowing healthcare providers to customize therapy based on individual patient needs and disease progression.

Global Ankylosing Spondylitis Market, Segmentation by Route of Administration

The Global Ankylosing Spondylitis Market has been segmented by Route of Administration into Oral and Parentral.

Oral administration, which includes drugs such as NSAIDs and corticosteroids, remains a popular choice due to its ease of use, convenience, and widespread availability. This route is particularly favored for managing mild to moderate symptoms, allowing patients to adhere to treatment regimens without the need for medical supervision.

Parenteral administration, encompassing injectable drugs like TNF inhibitors (e.g., Humira, Simponi, Remicade) and IL-17 inhibitors, is gaining prominence for treating moderate to severe cases of ankylosing spondylitis. This route provides higher bioavailability and quicker therapeutic effects, making it ideal for biologics and targeted therapies. Parenteral options are often administered in clinical settings or through self-injectable devices, enhancing patient flexibility while ensuring precise dosing.

The choice between oral and parenteral routes often depends on disease severity, patient compliance, and the pharmacological profile of the medication. As biologics and advanced therapies become more integral to the treatment landscape, the parenteral segment is expected to witness significant growth, driven by innovations in delivery systems and the increasing prevalence of severe ankylosing spondylitis cases.

Global Ankylosing Spondylitis Market, Segmentation by Distribution Channel

The Global Ankylosing Spondylitis Market has been segmented by Distribution Channel into Hospital Pharmacy, Retail Pharmacy, and Others.

Hospital Pharmacy plays a crucial role in the distribution of ankylosing spondylitis (AS) drugs, especially for severe cases requiring immediate medical intervention. Hospitals often have specialized pharmacists who ensure that patients receive the appropriate therapy tailored to their specific needs. Medications such as Cosentyx, Humira, and Remicade are frequently dispensed in hospitals due to the need for monitoring and follow-up care associated with these treatments. The advantage of hospital pharmacies lies in their capability to provide comprehensive patient care, including drug counseling and monitoring for adverse effects, which is particularly important for biologics used in treating AS. Retail Pharmacy, on the other hand, serves as a primary access point for patients managing their condition on an outpatient basis. This channel is characterized by convenience, allowing patients to obtain their prescriptions without the need for hospital visits. Retail pharmacies often carry a range of drugs, including those used for AS like Enbrel and Simponi. They typically offer additional services such as medication synchronization and consultation, which can enhance adherence to treatment regimens. The growing prevalence of ankylosing spondylitis is likely to drive demand in retail pharmacies, particularly as awareness and diagnosis rates increase.

Global Ankylosing Spondylitis Market, Segmentation by Geography

In this report, the Global Ankylosing Spondylitis Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Ankylosing Spondylitis Market Share (%), by Geographical Region, 2024

North America leads the global ankylosing spondylitis market, primarily due to advanced healthcare infrastructure, high awareness of inflammatory diseases, and the availability of a wide range of treatment options. The United States, in particular, has a significant market share, driven by the presence of major pharmaceutical companies and ongoing investments in research and development for new biologics. Additionally, the increasing incidence of ankylosing spondylitis and supportive reimbursement policies further bolster market growth in this region. Europe holds a substantial share of the ankylosing spondylitis market, benefiting from a well-established healthcare system and a growing emphasis on patient-centered care. Countries like Germany, France, and the United Kingdom are leading the charge in adopting advanced treatment modalities. The region also experiences a rising trend toward personalized medicine, which enhances treatment outcomes for patients. However, variations in healthcare policies and access to medications across European countries can impact market dynamics. Asia Pacific is witnessing rapid growth in the ankylosing spondylitis market, fueled by increasing awareness of the disease, improving healthcare facilities, and a rise in disposable incomes. Countries such as China and India are emerging as key players in the market, with growing populations and a higher prevalence of ankylosing spondylitis. The increasing adoption of biologics and targeted therapies is expected to drive market expansion in this region, despite challenges such as limited access to advanced treatments in rural areas.

In the Middle East and Africa, the ankylosing spondylitis market is gradually developing, influenced by rising healthcare investments and efforts to improve disease awareness. While the market potential is significant, challenges such as limited healthcare infrastructure and varying access to treatment options can hinder growth. However, countries like South Africa and the United Arab Emirates are making strides in enhancing their healthcare systems, which may positively impact market dynamics. Latin America is also experiencing growth in the ankylosing spondylitis market, driven by increasing healthcare expenditure and the rising prevalence of chronic inflammatory diseases. Brazil and Mexico are key markets in this region, with efforts to improve access to biologic therapies. However, challenges such as economic instability and varying healthcare policies may affect market growth.

This report provides an in depth analysis of various factors that impact the dynamics of Global Ankylosing Spondylitis Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Increasing prevalence and diagnosis of ankylosing spondylitis
• Advancements in biologic therapies and treatment options
• Growing aging population susceptible to autoimmune diseases
• Expanding healthcare infrastructure and access to treatment

• Rising patient awareness and advocacy efforts- The emergence of various patient advocacy groups has played a pivotal role in educating individuals about the symptoms, potential complications, and available treatment options for ankylosing spondylitis. These organizations conduct outreach programs, webinars, and workshops to inform patients about the importance of recognizing early signs, such as persistent back pain and stiffness, which are often misattributed to normal aging or other musculoskeletal issues. As patients become more knowledgeable, they are more likely to seek medical advice sooner, facilitating earlier diagnoses and improved outcomes. Additionally, advocacy efforts have contributed to increased visibility of AS within the healthcare system, prompting healthcare professionals to prioritize research and development of new therapeutic options. This growing recognition has led to enhanced funding for clinical trials, ultimately resulting in a broader array of available treatments for patients. With new biologic therapies such as Cosentyx and Humira gaining traction, patients have access to more effective management strategies, reducing the disease's impact on their quality of life. Moreover, social media platforms and online communities have become powerful tools for sharing personal experiences and treatment journeys. Patients can connect with others facing similar challenges, creating a support network that encourages adherence to treatment plans and promotes proactive health management. This sense of community not only empowers individuals but also fosters a collective voice advocating for better healthcare policies, access to treatments, and improved patient care standards.

  As awareness continues to rise, it also leads to greater demand for healthcare services and therapies specifically designed for AS. Pharmaceutical companies are increasingly motivated to invest in the development of new drugs and treatment modalities that cater to the needs of this patient population. This surge in demand translates into a more dynamic and competitive market, ultimately benefiting patients through improved access to innovative therapies.

Restraints:

• High cost of biologic medications and long-term treatment

• Stringent regulatory requirements for drug approval- Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose rigorous standards to ensure the safety, efficacy, and quality of pharmaceuticals before they reach the market. These requirements involve comprehensive preclinical and clinical testing, which can take several years and substantial financial investment.

  The lengthy and complex approval process can delay the introduction of new therapies for ankylosing spondylitis, leaving patients with limited treatment options. Developers of novel drugs must conduct extensive clinical trials that include multiple phases, often requiring thousands of participants to assess the long-term safety and effectiveness of the treatments. These trials can be challenging to design and execute, particularly for diseases like ankylosing spondylitis that have varied manifestations and patient responses. Moreover, the high costs associated with meeting these regulatory requirements can deter smaller biotechnology firms and startups from pursuing innovative therapies. The need for substantial investment in research and development, along with the costs of compliance with regulatory standards, can limit the number of players in the market. As a result, fewer new drugs may enter the market, reducing competition and potentially leading to higher prices for existing therapies. Additionally, regulatory bodies often require post-marketing surveillance to monitor the long-term effects of drugs, adding another layer of complexity to the drug approval process. This ongoing scrutiny can prolong the timeline for launching new treatments and may lead to increased costs for pharmaceutical companies.

  The stringency of regulatory requirements can also contribute to uncertainty in drug development, as changes in regulatory guidelines or increased scrutiny can impact timelines and project viability. This uncertainty can make it challenging for companies to plan and allocate resources effectively.

Opportunities:

• Development of personalized medicine approaches for AS

• Expansion of telemedicine and digital health solutions- Global Ankylosing Spondylitis Market, revolutionizing the way patients manage their condition and access healthcare services. Telemedicine enables patients with ankylosing spondylitis (AS) to consult healthcare providers remotely, thereby overcoming geographical barriers and enhancing access to specialized care. This is particularly beneficial for individuals living in rural or underserved areas, where access to rheumatologists and specialized AS care may be limited.

  With the growing emphasis on remote patient monitoring, telemedicine platforms can facilitate regular check-ins and consultations without the need for in-person visits. Patients can discuss their symptoms, medication adherence, and treatment responses with healthcare professionals through video calls, phone calls, or secure messaging. This continuous interaction allows for timely interventions and adjustments to treatment plans, ultimately leading to improved patient outcomes. The convenience of telemedicine can also encourage patients to seek care more frequently, reducing the risk of complications associated with delayed treatment. Digital health solutions, including mobile health applications and wearable devices, further enhance this opportunity by providing patients with tools to track their symptoms, medication schedules, and overall health status. These applications can offer educational resources about ankylosing spondylitis, empowering patients with knowledge about their condition and encouraging proactive management. Additionally, features such as reminders for medication intake, exercise routines, and pain management techniques can improve adherence to treatment regimens, which is crucial for controlling symptoms and preventing disease progression.

  The integration of artificial intelligence (AI) and data analytics into telemedicine platforms can also lead to personalized treatment plans based on individual patient data. By analyzing patient-reported outcomes and biometrics, healthcare providers can tailor interventions to meet the specific needs of each patient, resulting in more effective management of AS. Moreover, the rise of telehealth has been accelerated by the COVID-19 pandemic, leading to increased acceptance of virtual care among both patients and healthcare providers. This shift is likely to continue, fostering a more patient-centric approach in the management of chronic conditions like ankylosing spondylitis.

Key players in Global Ankylosing Spondylitis Market include:

• AbbVie, Inc.
• Amgen, Inc.
• Pfizer, Inc.
• UCB, Inc.
• Novartis AG
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Izana Biosciences
• Zydus Lifesciences Ltd.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis